X
[{"orgOrder":0,"company":"AiViva Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AiViva Biopharma Announces Positive Data from Phase 1\/2a Clinical Trial of AIV001 for Dermal Scarring and Wound Healing","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"AiViva Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AiViva Biopharma Initiates Phase 1\/2 Clinical Trial of AIV001 for Nonmelanoma Skin Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"AiViva Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AiViva Biopharma Initiates Phase 1 Clinical Trial of AIV007 for Age-Related Macular Degeneration and Diabetic Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I"}]
Find Clinical Drug Pipeline Developments & Deals by AiViva Biopharma
Filters
Companies By Therapeutic Area
Details:
AIV007 is a novel formulation using our JEL™ Technology designed for prolonged drug release. AIV007 targets multiple pathways including VEGFR, PDGFR, and FGFR to address neovascularization and fibrosis.
Lead Product(s):
Lenvatinib
Therapeutic Area: Ophthalmology
Product Name: AIV007
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 22, 2023
Details:
Second clinical trial assessing AIV001 to address unmet needs of skin diseases building on the exploratory efficacy of AIV001 in an earlier trial in wound healing from surgical incision. AIV001 to be tested in patients with superficial or nodular basal cell carcinoma.
Lead Product(s):
AIV001
Therapeutic Area: Oncology
Product Name: AIV001
Highest Development Status: Phase I/ Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 02, 2020
Details:
AIV001 was shown to be safe and well tolerated after local intradermal treatment of incisional wounds. Reduction in fibrosis was observed from single AIV001 treatment post-wounding.
Lead Product(s):
AIV001
Therapeutic Area: Trauma (Emergency, Injury, Surgery)
Product Name: AIV001
Highest Development Status: Phase I/ Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 25, 2020